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Background: Cystic Fibrosis (CF) lung disease is characterised by an inexorable decline in lung function, punctuated by periods of symptomatic
worsening known as pulmonary exacerbations (referred to here as CFPE). Despite their clinical significance, the cause of CFPE remains
undetermined. It has been suggested that an increase in bacterial density may be a trigger, although this has not been shown empirically.
Methods: Here, a previously validated quantitative PCR-based approach was used to assess numbers of Pseudomonas aeruginosa and of total
bacteria in respiratory secretions from patients during the period leading up to CFPE. Sputum samples collected from 12 adult CF patients were
selected retrospectively to fall approximately 21, 14, 7 and 0 days prior to CFPE diagnosis. In addition, the relationships between clinical
parameters (FEV1, temperature and patient reported outcome measures) and microbiological data were investigated.
Results: No significant changes either in total bacterial or P. aeruginosa numbers were identified prior to CFPE. Of all the correlations tested, only
temperature showed a significant correlation with total bacterial numbers in the period leading to CFPE.
Conclusions: These findings strongly suggest that CFPE do not generally result from increased bacterial density within the airways. Instead, data
presented here are consistent with alternative models of pulmonary exacerbation.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Bacterial enumeration infection molecular respiratory1. Introduction
Pulmonary disease in adult cystic fibrosis (CF) patients is
typified by chronic polymicrobial lung infections [1] with intermit-
tent periods of pulmonary exacerbation (referred to here as CFPE).
CFPE presents clinically with changes in cough, sputum produc-☆ A subset of preliminary data for this study was presented at the 24th North
American Cystic Fibrosis Conference, 20–24th of October 2010, Minneapolis,
USA [48].
⁎ Corresponding author. Tel.: +44 207 848 4467; fax: +44 207 848 4500.
E-mail address: geraint.rogers@kcl.ac.uk (G.B. Rogers).
1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.05.002tion, dyspnoea, decreased energy level and appetite, weight loss
and decreases in spirometric parameters [2]. These periods of
exacerbation affect quality of life of CF patients [3] and have been
considered to be both the single most important cause of CF mor-
bidity [4] and strong predictors of 5 year survival [5]. Exacerba-
tions are risk factors for a more rapid lung function decline [6], and
recent evidence indicates that loss of lung function that occurs
during exacerbations can be permanent [7]. Despite their im-
portance to CF patient health, the triggers for the onset of CFPE
remain unknown.
Given the infective nature of CF lung disease, the initiation
of CFPE has generally been considered to represent a shift in thed by Elsevier B.V. All rights reserved.
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biology. Changes in this balance impact on sputum production
and airflow obstruction, and may be influenced by factors such
as respiratory viral infections [8], fungal presence [9] and air
pollution [10]. Antibacterial agents are routinely administered at
times of CFPE to reduce symptoms and improve lung function
[11,12]. Further, regular maintenance antibiotic treatment may
be used in an attempt to decrease CFPE frequency [1]. How-
ever, some studies have failed to demonstrate a clear relation-
ship between the impacts of antibiotics on bacterial density and
clinical outcomes during treatment for CFPE [13]. Further,
antibiotics that alter the behaviour, but not viability, of CF
pathogenic bacteria can decrease risk of exacerbations [14].
Therefore, whether a simple increase in the number of bacteria
present in respiratory secretions prior to the onset of CFPE acts
as a direct trigger, or whether a change in the behaviour of
colonising species, or other as yet unknown factors, are required,
remains unclear.
To date, little quantitative analysis has been performed to
investigate whether bacterial density increases prior to CFPE.
This may be partly due to the lack of a universally accepted
methodology for quantitative analysis [15]. In addition, whilst
useful information can be gained from culture-based enumer-
ation of bacterial cells in CF respiratory samples, the technique
is associated with a level of inherent inaccuracy due to a number
of factors, including the presence of slow-growing bacterial
variants [16] and potentially viable but non-culturable bacterial
cells [17,18], as well as the viscous nature of CF respiratory
secretions, resulting in incomplete homogenisation and sam-
pling errors [15].
The application of culture-independent quantitative (Q)-PCR
potentially offers a more accurate means by which changes in
bacterial numbers prior to the onset of CFPE can be char-
acterised [19], regardless of whether species are refractory to in
vitro culture [20]. Q-PCR technology is well-validated and used
widely in the characterisation of bacteria in clinical samples [21],
and has been shown to be a sensitive, accurate and reproducible
method of bacterial enumeration in samples of CF airway secre-
tions [22,23]. However, where clearance of material from the
site of infection is poor, as in the lower CF airways [24], the
presence of nonviable cells and extracellular DNA can have a
substantial impact on the accuracy of quantification by mole-
cular methods. To address this, new molecular protocols have
been developed that exclude from analysis any DNA not derived
from viable bacterial cells [25]. These protocols, involving
propidium monoazide (PMA) photo-crosslinking chemistry to
block extracellular DNA or DNA from non-viable cells from
serving as a template for PCR reactions, have been adapted to,
and validated in, the CF respiratory context [26]. Further, they
have been shown to be capable of identifying short-term changes
in bacterial levels in sputum not detected by standard Q-PCR
techniques, such as a reduction in bacterial density in CF respi-
ratory secretions following the intravenous (IV) administration
of certain antibiotics [27].
The aim of this study was to determine whether a relationship
exists between bacterial density in airway secretions and the
onset of CFPE in adult CF patients with chronic lung infections.Q-PCRwas used to determine levels of viable P. aeruginosa and
total bacterial cells in PMA-treated sputum samples in the period
prior to exacerbation. Further, P. aeruginosa and total bacterial
density were compared with clinical signs (FEV1, temperature)
and patient reported outcome (PRO) scores (sputum production,
cough severity, breathlessness, and general well-being).
Here, we report no significant link between the abundance of
bacteria in respiratory secretions and the onset of CFPE, and
discuss the relationship of these findings to our current under-
standing of respiratory health in CF patients.
2. Materials and methods
2.1. Clinical samples
Patients were recruited for this study under local ethical ap-
proval from Southampton and South West Hampshire Research
Ethics Committee (06/Q1704/26). Twelve adult CF patients from
Southampton General Hospital, UK were followed over a period
of 1 year with sputum samples collected and archived 2–3 times
per week. This work was performed within the context of a wider
investigation of the dynamics of CF lung disease. Patients were
selected on the basis of four criteria: consistent sputum produc-
tion, anticipated frequent exacerbations (here, low relative FEV1
scores were taken to indicate more severe respiratory disease, and
a greater likelihood of exacerbation), chronic P. aeruginosa in-
fection (defined as at least 3 positive sputum cultures in the pre-
vious 12 months, in accordance with the modified Leeds criteria
[28]), and no change over the past 12 months in maintenance
therapy (nine patients received a macrolide antibiotic, seven
patients received nebulised colomycin, patient 10 received ne-
bulised tobramycin, and patient 8 and 11 received nebulised
colomycin/tobramycin in alternating months, Table 1). Over the
study period all patients experienced at least two periods of CFPE,
as diagnosed using the scheme described previously by Fuchs
et al. [29] (Table 1).
Archived samples were selected retrospectively for analysis
that fell approximately 21, 14, 7 and 0 days prior to the start of
antibiotic treatment for CFPE. Periods of CFPE were selected
where the patient had not received antibiotics less than 21 days
prior to the first sampling point (42 days prior to start of CFPE).
There were two exceptions to these criteria; CFPE 2, Patient 1,
and CFPE 5, Patient 7, where, in each case, a course of anti-
biotics had finished 8 days prior to day −21. Of the 39 periods
of CFPE experienced by the 12 patients in the study, samples
were available at all four of the sampling time points in 28
cases, and samples were available at three of the sampling time
points in 6 cases. For the remaining five CFPE, samples were
available for fewer than three of the sampling points, and these
CFPE were excluded from further analysis. The 6 CFPE with
three available time points (CFPE 2, Patient 1, CFPE 2, 3 and 4,
Patient 4, CFPE 3, Patient 9 and CFPE 2, Patient 10) were
included for all analyses in this manuscript apart from the re-
gression analysis and the repeated measures one way ANOVA.
Sputum samples were selected for analysis that fell 3 weeks,
2 weeks and 1 week prior to the start of antibiotic treatment and
a fourth sample at the diagnosis of exacerbation, and/or prior
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359F.A. Stressmann et al. / Journal of Cystic Fibrosis 10 (2011) 357–365to antibiotic treatment. Samples were collected within a range
of days prior to diagnosis of CFPE: 18–24 days, 11–17 days,
4–10 days and 0 days at the start of CFPE. These are referred to
as weeks 3, 2, 1 and 0, respectively or as the time points ‘−21’,
‘−14’, ‘−7’ and ‘0’ days. Antibiotic therapy forCFPEwas initiated
on day 0 for all patients, however “day 0” sputum samples were
collected prior to their administration.
The majority of patients provided sputum samples as part of
their normal morning treatment routine, however some patients
chose to produce samples in the evening. In such cases, samples
were stored at 4 °C and collected by a courier the following
morning. All patients gave sputum samples consistently at their
chosen time of day. All sputum samples were stored (immedi-
ately after expectoration) and shipped at 4 °C. Samples were left
at 4 °C for a maximum of 36 h (in accordance with the sputum
handling guidelines of the Health Protection Agency, BSOP57).
Once material had been removed for culture-based analysis,
sputum samples were stored −80 °C prior to processing for
molecular analysis.
2.2. Clinical data
Clinical measures (FEV1 in litres, temperature) were recorded
at the time of collection for each sample. In addition, PRO scores
(“breathlessness”, “cough severity”, “sputum production”, and
“general well-being”) were recorded using visual analogue
scores (VAS) by means of a symptom sheet. VAS were recorded
in millimetres from 0 (no symptoms) to 100 (worst symptoms).
2.3. PMA cross-linking and DNA extraction
Sputum samples were removed from −80 °C storage and
homogenised by hand. 250 μl portions were processed for DNA
cross-linking using PMA and nucleic acid extraction as described
previously by Rogers et al. [26].
2.4. Quantitative PCR
All quantitative PCR analyses were performed in triplicate.
Total bacterial density was determined using a Taqman assay, in
which a 466 bp fragment of the 16S ribosomal RNA gene was
amplified, as described previously [20]. P. aeruginosa density
was determined using a Taqman assay which amplified a 65 bp
fragment of the regA gene, as described previously [30]. Details
of the relevant primers and probes used are shown in Table 2.
Total bacterial primers and probe were used at a concentration
of 100 nM each, whereas P. aeruginosa-specific primers were
used at a concentration of 1000 nM each, and the probe at a
concentration of 250 nM. 1 μl (~800 ng) of mixed template
DNA (human and microbial) was used in the P. aeruginosa
assay. 1 μl of a 100 fold dilution (~8 ng) was used in the total
bacterial assay. All PCR reactions were carried out in a total
volume of 25 μl in Taqman®Universal PCRMastermix (Applied
Biosystems, Warrington, UK). Quantitative PCR assays were
carried out using the Rotorgene 6000 (Qiagen, Crawley, UK)with
a temperature profile of 50 °C for 2 min, 95 °C for 10 min,
followed by 45 cycles at 95 °C for 15 s and 60 °C for 60 s.
Table 2
PCR primers and probes used in this study.
Primer Primer type Sequence (5′ to 3′) Reference
EubF Total bacterial forward TCCTACGGGAGGCAGCAGT [20]
EubR Total bacterial reverse GGACTACCAGGGTATCTAATCCTGTT [20]
EubPR Total bacterial Taqman probe FAM–CGTATTACCGCGGCTGCTGGCAC–TAMRA [20]
PaerF P. aeruginosa forward TGCTGGTGGCACAGGACAT [30]
PaerR P. aeruginosa reverse TTGTTGGTGCAGTTCCTCATTG [30]
PaerPR P. aeruginosa Taqman probe FAM–CAGATGCTTTGCCTCAA–TAMRA [30]
Fig. 1. Variation in total bacterial density and P. aeruginosa density three weeks
prior to antibiotic therapy for increased severity of respiratory symptoms. Trend
in mean log cfu/ml equivalent for total bacterial and P. aeruginosa density prior
to CFPE onset for all 34 exacerbations. Bacterial density is expressed as
log cfu ml−1 of sputum equivalent (y axis) over the days preceding exacerbation
(x axis). Time points are plotted as ‘−21’, ‘−14’, ‘−7’ and ‘0’, relating to days
prior to CFPE onset, however, some sample points did not fall on these exact
days prior to CFPE. For the observed P. aeruginosa means, rises and falls from
0.7 to 0.75 (log values) were the minimal changes that would have resulted in a
statistically significant (Pb0.05) effect. For the observed total bacterial means,
rises and falls of 0.2 to 0.6 (log values) were the minimal changes that would
have resulted in a statistically significant (Pb0.05) effect.
360 F.A. Stressmann et al. / Journal of Cystic Fibrosis 10 (2011) 357–365For both total bacterial and P. aeruginosa-specific quantitative
PCR assays, densities (cfu/ml) were determined by comparison
with standard curves generated from bacterial isolates. Separate
nutrient broth cultures of methicillin sensitive Staphylococcus
aureus (MSSA: ATCC 29213), P. aeruginosa (NCTC 12934/
ATCC 27853), Streptococcus pyogenes (ATCC 19615) and
Escherichia coli (NCTC 12241/ATCC 25922) isolates were
incubated at 37 °C for 16 h, with cfu ml−1 estimated by incu-
bation of dilutions (n=4) on Columbia Blood Agar at 37° for
24 h, followed by colony counts. DNA was extracted from ten-
fold dilutions of these broth cultures in the same way as for the
sputum samples, and RT-PCR was carried out as above on the
DNA extracts. The total bacterial assay was tested against the
standard curves of all species (P. aeruginosa, MSSA, S. pyogenes
and E. coli) to test for any variation in density estimation between
different species with different 16S ribosomal RNA gene copy
numbers. The standard curve generated using P. aeruginosa was
used for both P. aeruginosa and total bacterial enumeration to
allow direct comparisons to be made.
2.5. Statistical analysis
Statistical analyses were performed using SPSS Statistics
16.0 (SPSS Inc., Chicago, USA). The data were tested for nor-
mality and homogeneity of variance, and cell densities were
log10 transformed. Data were analysed by GLM repeated mea-
sures one way ANOVA, using Mauchly's Sphericity Test with
‘Week’ (4 levels) as the within-subjects factor. Linear regression
and correlations were calculated using SPSS. Means given are
averages of Log10 values. Simple Interactive Statistical Analysis
(http://www.quantitativeskills.com/sisa/) was used to calculate
Bonferroni corrections for the correlations.
3. Results
3.1. Total bacterial and P. aeruginosa sputum densities prior
to the start of IV antibiotic treatment
Viable total bacterial densities ranged from 3.5×106 cfu ml−1
to 5.9×1012 cfu ml−1, and viable P. aeruginosa densities ranged
from 5.3×103 cfu ml−1 to 1.8×1011 cfu ml−1. Mean values for
each time point for the sample set as a whole (34 periods of CFPE)
are shown in Fig. 1, (with mean FEV1 values for these time points
shown in Figure 2). For days −21, −14, −7, and 0, mean total
bacterial density values of 9.6×109, 1.9×1010, 1.8×1010
and 1.0×1010 cfu ml−1 were obtained respectively. Correspond-ing mean P. aeruginosa densities for these sample points were
5.8×107, 6.9×107, 9.0×107 and 8.5×107 cfu ml−1, respectively.
Repeated measures one way ANOVA was used to test for
significant differences between mean density values at each of
the four time points (CFPE 2, Patient 1, CFPE 2, 3 and 4, Patient
4, CFPE 3, Patient 9 and CFPE 2, Patient 10 were excluded
from these analyses due to there being only 3 data points). Mean
log bacterial densities did not differ significantly between the
four sampling points either for mean total bacterial density
(F3,81 =1.608, p=0.208) or mean P. aeruginosa density
(F3,81=0.348, p=0.791).
3.2. Identification of trends in total bacterial and P. aeruginosa
density prior to antibiotic treatment in individual patients
To test for significant rises or falls in bacterial densities (total
and P. aeruginosa) prior to each exacerbation linear regressions
}Fig. 2. Variation in FEV1 3 weeks prior to antibiotic therapy for increased
severity of respiratory symptoms. Trend in mean FEV1 prior to CFPE onset for
all 34 CFPE. FEV1 is expressed in litres (y axis) over the days preceding
exacerbation (x axis). In the case of Patient 7, it was not possible to collect
spirometric data due to the poor respiratory health of the patient. Time points are
plotted as ‘−21’, ‘−14’, ‘−7’ and ‘0’, relating to days prior to CFPE onset,
however, some sample points did not fall at these exact times. FEV1 values for
the individual patients are shown in Supplementary Fig. 2.
361F.A. Stressmann et al. / Journal of Cystic Fibrosis 10 (2011) 357–365were fitted to the data (excluding the CFPE with three time
points). In each case, the rate of change, the slope, of the re-
gression line over the four time points, and the statistical sig-
nificance of the change, is presented as Log10-fold/day change
(Table 3). Of the 28 CFPE, four showed a significant trend in
total bacterial density. Specifically, in Patient 3, CFPE 1, total
bacterial density increased significantly at an average of 0.03
per day (p=0.03), and in Patient 6, CFPE 3, Patient 8, CFPE 1,
and Patient 9, CFPE 2, the total bacterial density decreased
significantly at an average of −0.07 (p=0.05), −0.09 (p=0.05)
and −0.02 (p=0.05) per day respectively (Table 3).
For P. aeruginosa, only three of 28 exacerbations showed a
significant change in density over the four time points. Speci-
fically, in Patient 4, CFPE 5, P. aeruginosa density decreased
significantly at an average of −0.04 per day (p=0.017), In
Patient 5, CFPE 1, P. aeruginosa density decreased signifi-
cantly at an average of −0.04 per day (p=0.009), and in Patient
7, CFPE 1, P. aeruginosa density increased significantly at an
average of 0.12 per day (p=0.05). Examples of trends in total
bacterial and P. aeruginosa densities for individual CFPE are
shown for three patients in Supplementary Fig. 1.
3.3. Correlations between bacterial density, “time prior to
CFPE”, and clinical data
Correlation analysis was performed on the entire dataset and
was used to test, in a pair-wisemanner, for significant relationships
between any of the nine variables relating to the samples. These
variables included two clinicalmeasures—FEV1 and temperature
(with ranges of 0.7–3.1 L, and 35.4–37.9 °C, respectively), four
PRO scores— sputumproduction, cough severity, breathlessness,and general well-being (ranges 2–81 mm, 2–78 mm, 1–80 mm,
and 1–76 mm, respectively), time before CFPE, and total bacterial
andP. aeruginosa densities. Twelve significant relationshipswere
identified, shown in Table 4.
The only variables that correlated significantly with total
bacterial density prior to CFPE were P. aeruginosa density and
temperature (p= 0.0001, n= 132 and 127 respectively)
(Table 4). No other significant correlations were identified
with P. aeruginosa density. Two significant correlations were
identified for time before CFPE (sputum production, p=0.031,
n=128, and cough severity, p=0.019, n=128).
Eight significant correlations were identified amongst clinical
signs and PRO scores. Correlations between sputum production,
general well-being, cough and breathlessness were all highly
significant (pb0.0001, N=128 for all). Temperature signifi-
cantly correlated with sputum (p=0.001, n=127) and cough
(p=0.011, n=127).
4. Discussion
Despite the impact that episodes of pulmonary exacerbation
have on the respiratory health and quality of life of CF patients,
the reasons for their occurrence remain undetermined. This poor
understanding of the underlying causes for the onset of CFPE
hampers both the design of strategies to reduce the incidence of
CFPE, and the ability to design and deliver effective, timely
clinical therapy.
Antibiotic therapy represents a central component in the
treatment of CFPE [1]. The use of antibiotics in this context is
associated with an alleviation of respiratory symptoms, and
improved patient outcome measures [11,31]. Despite the bene-
fits associated with treatment strategies that might be expected
to reduce bacterial numbers, there is no evidence that changes in
the density of bacteria in the airways influence either the onset
of CFPE or FEV1.
It has been noted in at least one antibiotic trial that average
improvement in lung function did not correlate well with
changes in density of P. aeruginosa [31,32], and subjects in that
trial in whom lung function improved with antibiotic treatment
did not necessarily experience a drop in P. aeruginosa density
(personal communication, B. Ramsey). Other studies have
noted a poor correlation between bacterial density and measures
of inflammation [33], and between these measures and either
systemic symptoms or FEV1 [12]. Nevertheless, a potential link
between changes in bacterial numbers and the onset of CFPE
remained plausible, influencing the manner in which antibiotics
are usually administered, with high dose, combination therapy
designed to maximise the reduction of viable bacterial cells in
the airways. Whilst only one of many suggested triggers for the
onset of CFPE, it is the possible link with an increase in the
levels of the key CF pathogen P. aeruginosa, or airway bacteria
generally, that is the focus of the study presented here.
Here, the start of an exacerbation was defined clinically as
the initiation of antibiotic therapy administered in response to a
worsening of respiratory symptoms, as used previously [29].
Whilst no universally accepted definition or measure exists to
define the actual onset of an episode of CFPE [1,34], the start
Table 3
Summary of linear regressions fitted to trends in total bacterial and P. aeruginosa density prior to and at onset of CFPE, and total bacterial and P. aeruginosa density 21 and 0 days prior to onset of CFPE.
Patient CFPE Total bacteria P. aeruginosa
Rate of
change
(Log10-fold/day)
Significance
(p)
Density
(cfu/ml)
on day
−21
SD Density
(cfu/ml)
on day
0
SD Rate of
change
(Log10-fold/day)
Significance
(p)
Density
(cfu/ml)
on day
−21
SD Density
(cfu/ml)
on day
0
SD
1 1 −0.068 0.094 3.5×1010 2.1×109 1.9×109 3.3×107 0.082 0.524 5.3×103 1.2×103 1.5×105 8.7×104
1 3 0.022 0.836 4.1×107 6.1×106 3.9×108 9.9×106 0 0.978 3.5×106 6.6×105 6.0×106 7.2×105
2 1 0 0.955 2.9×109 7.0×107 2.2×109 2.3×108 −0.004 0.889 6.1×106 3.6×106 3.2×106 1.1×106
2 2 −0.065 0.404 7.8×1010 2.5×109 1.4×109 4.9×108 −0.011 0.596 8.7×109 2.0×108 3.6×109 5.3×107
3 1 0.034 0.026 ⁎ 1.1×1010 1.4×109 5.0×1010 2.5×109 −0.01 0.762 1.6×105 2.4×104 1.5×105 1.9×104
3 2 0.023 0.571 1.1×109 1.6×107 2.9×109 4.3×107 −0.028 0.125 2.0×107 2.0×106 5.2×106 1.6×106
4 1 0.087 0.289 5.1×1010 2.2×109 5.9×1012 1.9×1010 −0.013 0.804 4.1×108 2.3×107 2.1×108 2.9×106
4 5 −0.002 0.918 2.3×1010 3.4×109 1.7×1010 2.9×109 −0.043 0.017 ⁎ 5.0×109 3.0×108 8.6×108 2.9×107
5 1 −0.018 0.101 7.3×1010 6.9×108 3.7×1010 1.8×108 −0.037 0.009 ⁎ 4.0×108 2.1×108 8.0×107 2.6×107
5 2 −0.035 0.194 2.8×1010 1.8×108 5.6×109 2.6×107 −0.022 0.323 1.7×109 4.4×108 6.9×108 9.7×107
6 1 0.089 0.29 2.2×108 1.8×107 4.1×1010 6.9×109 0.075 0.393 9.6×105 3.6×105 8.3×107 2.3×106
6 2 0.001 0.961 1.1×1010 7.0×109 1.0×1010 3.1×109 −0.011 0.637 3.2×107 2.0×107 2.0×107 2.6×106
6 3 −0.074 0.045 ⁎ 4.9×1010 1.7×109 1.2×109 2.6×106 −0.013 0.663 6.0×107 4.4×107 3.8×107 9.7×106
7 1 0.038 0.275 3.9×109 5.4×108 2.8×1010 1.5×109 0.117 0.047 ⁎ 7.3×106 4.2×105 2.1×109 1.1×108
7 2 −0.031 0.348 4.7×1010 3.8×109 5.4×109 2.6×108 −0.016 0.707 7.6×107 8.3×106 1.8×107 5.2×106
7 3 0.025 0.572 4.5×1010 6.2×109 3.8×1011 8.0×109 0.036 0.329 8.1×107 6.1×106 5.3×108 9.8×106
7 4 0.001 0.959 1.5×1011 3.7×1010 1.7×1011 4.5×1010 −0.022 0.575 1.1×109 4.6×107 4.0×108 2.4×107
7 6 0.002 0.865 7.8×1010 4.9×109 1.0×1011 2.8×1010 0 0.994 1.8×109 5.4×107 2.8×109 5.3×107
8 1 −0.086 0.046 ⁎ 6.7×1010 9.9×108 5.1×108 2.1×108 −0.078 0.052 1.0×109 5.5×107 1.8×107 1.0×107
8 3 0.078 0.12 2.0×108 1.4×108 1.1×1010 2.4×109 −0.011 0.459 6.7×108 1.6×107 5.6×108 8.9×107
9 1 0.069 0.245 3.1×108 1.8×108 3.0×1010 1.1×1010 0.12 0.256 9.0×104 4.4×104 2.6×108 1.2×108
9 2 −0.031 0.043 ⁎ 1.3×1010 1.1×1010 3.2×109 2.1×109 −0.039 0.065 6.3×107 2.3×107 1.1×107 4.7×106
10 1 0.036 0.371 2.7×109 9.9×108 2.6×1010 2.0×109 0.061 0.639 2.2×107 2.7×106 4.0×107 2.7×107
10 3 −0.062 0.159 2.1×1010 1.4×1010 7.4×108 4.0×108 −0.059 0.105 1.2×109 1.0×108 5.6×107 4.5×107
11 1 −0.018 0.718 9.3×109 2.9×109 1.3×108 9.1×107 −0.009 0.799 2.6×109 2.9×108 7.6×109 4.7×108
11 2 −0.084 0.327 1.1×1011 1.4×1010 2.0×1010 4.9×109 0.018 0.471 4.3×108 2.1×108 1.9×108 1.1×108
12 1 0.1 0.085 3.3×108 1.5×108 2.0×1010 2.4×108 0.173 0.13 3.1×104 1.1×104 2.5×107 5.6×105
12 3 −0.03 0.386 3.3×1010 9.2×109 6.2×109 5.6×108 −0.029 0.687 7.6×109 1.9×107 4.1×109 1.1×106
The table shows the slope and significance of the linear regressions. The slope, or rate of change, is expressed as the Log10-fold change per day (the change in the Log10 density per day), with the sign of the fold change
indicating an increasing or decreasing trend. Total bacterial and P. aeruginosa densities (and respective standard deviations (SD)) are expressed in cfu ml−1 of sputum on day −21 and 0 prior to the onset of CFPE,
however, some sample points did not fall on these exact days prior to CFPE. The values for day −14 and day −7 are shown in Supplementary Table 1.
⁎ pb0.05.
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Table 4
Significant correlations between clinical variables, PRO scores and total
bacterial density and P. aeruginosa density.
Correlation of
clinical signs or
PRO scores with
Correlate 1 Correlate 2 Pearson
coefficient
R
Significance
(p)
n
Total bacterial
numbers
Log Ps Log Tot −0.374 0.0001 132
Temperature Log Tot −0.31 0.0001 127
–
Time Sputum Time 0.19 0.031* 128
Cough Time 0.207 0.019* 128
–
Self Sputum GWB 0.898 0.0001 128
Sputum Temperature 0.28 0.001 127
Cough Sputum 0.96 0.0001 128
Cough GWB 0.882 0.0001 128
Cough Temperature 0.224 0.011* 127
Breath Cough 0.827 0.0001 128
Breath Sputum 0.776 0.0001 128
Breath GWB 0.802 0.0001 128
Nine correlates (FEV1, temperature, sputum production, cough severity, breath-
lessness, general well-being (GWB), time before CFPE, total bacterial (Log Tot)
and P. aeruginosa (Log Ps) density) were tested for the pooled data for the 34
exacerbations analysed. Only significant correlations are shown (pb0.05). Bon-
ferroni corrections were performed on the comparisons. Values marked * denote
correlations where p would be greater than 0.05 after Bonferroni correction.
363F.A. Stressmann et al. / Journal of Cystic Fibrosis 10 (2011) 357–365date of antibiotics for respiratory worsening is used often
because it provides a clinically replicable, defined time point.
Because changes in bacterial density could precede the
symptomatic onset of an exacerbation, samples were selected
to encompass a three-week period prior to antibiotic therapy, an
interval that seemed adequate for capturing any related changes
in bacterial density should they occur.
Culture-independent analysis of respiratory samples was
performed using quantitative (Q)-PCR, which offers many po-
tential advantages over cultivation-based approaches to bacterial
enumeration, and has been employed extensively in awide range of
contexts [21]. Whilst a number of key issues must be considered
when using these culture-independent techniques, such as the
potential for incomplete cell lysis, nucleic acid degradation, and
PCR bias or inhibition [35], Q-PCR has been shown to be accurate
and reproducible in the analysis of CF airway samples [22,23].
Despite this, molecular quantification of viable bacteria in CF
respiratory secretions is challenging due to the persistence of
bacterial DNA from dead or lysed cells in airway mucus [24,36].
This DNA can contribute to PCR amplification, and thus result in
an overestimation of the true bacterial density present. In order to
remove this potentially confounding factor, clinical samples were
pre-treated with PMA, a method demonstrated previously to
restrict amplification to DNA templates derived only from viable
bacterial cells [26,27]. Previous, culture-based, studies of CF
respiratory secretions have reported between 106 and 109 colony
forming unit equivalents per ml of sample [37,38]. The bacterial
densities we observed using a Q-PCR-based approach agree well
with those previous studies, with mean densities of ~107 and
~1010 colony forming unit equivalents per ml for P. aeruginosaand total bacteria, respectively. Further, the difference between
total bacterial and P. aeruginosa densities was not unexpected,
given the many non-Pseudomonas species that are now known
to be present in CF airway secretions, often outnumbering
P. aeruginosa [39]. This study set out to determine whether a
clonal expansion of bacteria colonising the CF airways was a
trigger for the onset of CFPE. We identified no significant dif-
ferences in total bacterial or P. aeruginosa density amongst any of
the sampling points during the 3 weeks prior to antibiotics being
administered, or between any of those points and mean values for
the entire study. Whilst no evidence was found for a general trend
in bacterial density over the period leading up to treatment, we did
observe significant changes during this period in individual
patients. Nevertheless, the direction of these changes varied, and
they did not occur consistently for given patients, indicating that
they were unlikely to be causally related to exacerbations. How-
ever, in patients where no trend was observed, it is possible that
relatively high bacterial densities masked variations, that whilst
substantial, represented only a small proportion of the total bacteria
present.
The findings presented here also indicate little correlation
between bacterial density and either PRO measures or other
clinical variables. The only significant correlation found was
that between temperature and total bacterial density. Whilst a
decrease in FEV1 is often used clinically as an indication of
short-term decline in respiratory health, the absence of such a
decline seen here (regardless of airway disease severity), was
consistent with previous studies that demonstrated poor
correlation with exacerbation onset [40].
To the best of our knowledge, this is the first culture-
independent investigation of bacterial density in serially col-
lected sputum in the period preceding CFPE. The patient group
studied here was of limited size. Further, patients were selected
who had moderate to severe lung disease (as indicated by low
FEV1) in anticipation of a high likelihood of exacerbation, and
as such, do not represent a cross-section of CF patients.
However, three separate statistical analyses each failed to detect
significant trends, differences or correlations in the relationship
between bacterial density and onset of CFPE.
The data presented here suggest that the airway densities of P.
aeruginosa and/or total bacterial cells do not rise consistently in
the period prior to the onset of CFPE. However, if the volume of
sputum produced during this period increased, this might have the
effect ofmasking an increase in bacterial numbers due to a dilution
effect. The patient reported levels of sputum production indicate a
rise during this time. Nevertheless, the impact of any such increase
on bacterial density data is unknown, and would have to con-
sistently mirror changes in bacterial numbers in order to prevent
detection of bacterial trends. Previous work suggests that ex-
pectorated sputum rates change less than 10 fold between CFPE
and clinical stability [41]. However, the total volumes of sputum
produced by CF patients in the period prior to CFPE onset
warrants further investigation. It is possible that, whilst no trends
in total bacterial abundance were detected here, changes in the
abundance of individual non-pseudomonal species that represent
only a small proportion of the total bacterial community, could
play a role in precipitating CFPE. This possibility could be
364 F.A. Stressmann et al. / Journal of Cystic Fibrosis 10 (2011) 357–365investigated through the application of a wider range of species-
specific assays. Furthermore, investigation of changes in levels of
inflammatory or microbial biomarkers in the period prior to
exacerbationmight provide additional insight into themechanisms
ofCFPE onset, and the role played by bacterial density in this [42].
An increase in bacterial density in CF airway secretions is
only one proposed trigger for CFPE [11,43]. Changes in the
bacterial mode of growth [44], the occurrence of respiratory
viral infections [4,8,45,46], or changes in the expression of
virulence [47], might also be triggers of CFPE. For example,
certain P. aeruginosa virulence factors have been shown to be
elevated during periods of CFPE [47]. Factors such as these
could still underlie the observed impact of antibiotic treatment
during CFPE [43], but go undetected by the analytical ap-
proaches employed here. Analysis of bacterial gene expression,
as well as the investigation of acute viral infections, are
therefore likely to be important to include in future studies.
The data presented here challenge the model that periods of
CFPE are generally precipitated by a change in bacterial density
in the CF lower airway secretions. Given the focus of both short
and long-term antibiotic therapy in CF care on reducing bac-
terial load, these findings necessitate a reappraisal of the way in
which antibiotic strategies are designed. Further, identification
of factors that do trigger the onset of CFPE would provide both
novel opportunities for therapeutic intervention and the bio-
markers that are predictive of such episodes. As such, this
represents an important area of continuing investigation.
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